{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:40:06Z","timestamp":1792435206184,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s00520-026-11387-2","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T05:39:19Z","timestamp":1792388359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between prophylactic desloratadine use and docetaxel-induced skin toxicities in patients with early-stage breast cancer: an inverse probability-weighted retrospective cohort study"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4153-8555","authenticated-orcid":false,"given":"Katsuya","family":"Makihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayo","family":"Motomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Kimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomokazu","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"key":"11387_CR1","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1056\/NEJMoa043681","volume":"352","author":"M Martin","year":"2005","unstructured":"Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302\u20132313. https:\/\/doi.org\/10.1056\/NEJMoa043681","journal-title":"N Engl J Med"},{"key":"11387_CR2","doi-asserted-by":"publisher","first-page":"5664","DOI":"10.1200\/JCO.2006.07.3916","volume":"24","author":"H Roch\u00e9","year":"2006","unstructured":"Roch\u00e9 H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664\u20135671. https:\/\/doi.org\/10.1200\/JCO.2006.07.3916","journal-title":"J Clin Oncol"},{"key":"11387_CR3","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1200\/JCO.2006.06.5391","volume":"24","author":"SE Jones","year":"2006","unstructured":"Jones SE, Savin MA, Holmes FA, O\u2019Shaughnessy J, Blum JL, Vukelja S et al (2006) Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer (US Oncology 9735). J Clin Oncol 24:5381\u20135387. https:\/\/doi.org\/10.1200\/JCO.2006.06.5391","journal-title":"J Clin Oncol"},{"key":"11387_CR4","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B et al (2006) Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: NSABP B-27. J Clin Oncol 24:2019\u20132027. https:\/\/doi.org\/10.1200\/JCO.2005.04.1665","journal-title":"J Clin Oncol"},{"key":"11387_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jnci\/djm287","volume":"100","author":"P Francis","year":"2008","unstructured":"Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M et al (2008) Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: breast international group 02-98 randomized trial. J Natl Cancer Inst 100:121\u2013133. https:\/\/doi.org\/10.1093\/jnci\/djm287","journal-title":"J Natl Cancer Inst"},{"key":"11387_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","volume":"13","author":"L Gianni","year":"2012","unstructured":"Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC et al (2012) Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:25\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(11)70336-9","journal-title":"Lancet Oncol"},{"key":"11387_CR7","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278\u20132284. https:\/\/doi.org\/10.1093\/annonc\/mdt182","journal-title":"Ann Oncol"},{"key":"11387_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang CS, Thompson AM et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19:115\u2013126. https:\/\/doi.org\/10.1016\/S1470-2045(17)30716-7","journal-title":"Lancet Oncol"},{"key":"11387_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","volume":"26","author":"V Sibaud","year":"2016","unstructured":"Sibaud V, Leboeuf NR, Roche H, Belum VR, Gladieff L, Deslandres M et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26:427\u2013443. https:\/\/doi.org\/10.1684\/ejd.2016.2833","journal-title":"Eur J Dermatol"},{"key":"11387_CR10","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00520-013-1842-3","volume":"21","author":"MJ Poi","year":"2013","unstructured":"Poi MJ, Berger M, Lustberg M, Layman R, Shapiro CL, Ramaswamy B et al (2013) Docetaxel-induced skin toxicities in breast cancer patients subsequent to paclitaxel shortage: a case series and literature review. Support Care Cancer 21:2679\u20132686. https:\/\/doi.org\/10.1007\/s00520-013-1842-3","journal-title":"Support Care Cancer"},{"key":"11387_CR11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4081\/oncol.2020.442","volume":"14","author":"JJM Kwakman","year":"2020","unstructured":"Kwakman JJM, Elshot YS, Punt CJA, Koopman M (2020) Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 14:442. https:\/\/doi.org\/10.4081\/oncol.2020.442","journal-title":"Oncol Rev"},{"key":"11387_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2019.09.011","volume":"43","author":"YH Hsu","year":"2019","unstructured":"Hsu YH, Shen WC, Wang CH, Lin YF, Chen SC (2019) Hand-foot syndrome and its impact on daily activities in breast cancer patients receiving docetaxel-based chemotherapy. Eur J Oncol Nurs 43:101670. https:\/\/doi.org\/10.1016\/j.ejon.2019.09.011","journal-title":"Eur J Oncol Nurs"},{"key":"11387_CR13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/1078155208096111","volume":"15","author":"L Chew","year":"2009","unstructured":"Chew L, Chuen VS (2009) Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 15:29\u201334. https:\/\/doi.org\/10.1177\/1078155208096111","journal-title":"J Oncol Pharm Pract"},{"key":"11387_CR14","unstructured":"U.S. Food and Drug Administration (2024) Docetaxel injection prescribing information [Internet]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/203551s012lbl.pdf. Accessed 18 Oct 2026"},{"key":"11387_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.4103\/0973-1482.136025","volume":"10","author":"F Arshad","year":"2014","unstructured":"Arshad F, Bhat TS, Lone AR (2014) Docetaxel-induced Lyell\u2019s syndrome: a rare life-threatening cause of dermatitis medicamentosas. J Cancer Res Ther 10:742\u2013744. https:\/\/doi.org\/10.4103\/0973-1482.136025","journal-title":"J Cancer Res Ther"},{"key":"11387_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041208","volume":"15","author":"I Roger","year":"2023","unstructured":"Roger I, Montero P, P\u00e9rez-Leal M, Milara J, Cortijo J (2023) Evaluation of delayed-type hypersensitivity to antineoplastic drugs \u2013 an overview. Cancers (Basel) 15:1208. https:\/\/doi.org\/10.3390\/cancers15041208","journal-title":"Cancers (Basel)"},{"key":"11387_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/all.15113","volume":"77","author":"M Pagani","year":"2022","unstructured":"Pagani M, Bavbek S, Alvarez-Cuesta E, Berna Dursun A, Bonadonna P, Castells M, Cernadas J et al (2022) Hypersensitivity reactions to chemotherapy: an EAACI position paper. Allergy 77:388\u2013403. https:\/\/doi.org\/10.1111\/all.15113","journal-title":"Allergy"},{"key":"11387_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.jaci.2015.10.039","volume":"137","author":"M Picard","year":"2016","unstructured":"Picard M, Pur L, Caiado J, Giavina-Bianchi P, Galv\u00e3o VR, Berlin ST et al (2016) Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol 137:1154-1164.e12. https:\/\/doi.org\/10.1016\/j.jaci.2015.10.039","journal-title":"J Allergy Clin Immunol"},{"key":"11387_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","volume":"32","author":"ME Lacouture","year":"2021","unstructured":"Lacouture ME, Sibaud V, Gerber PA, van den Hurk C, Fern\u00e1ndez-Pe\u00f1as P, Santini D et al (2021) Prevention and management of dermatological toxicities related to anticancer agents: ESMO clinical practice guidelines. Ann Oncol 32:157\u2013170. https:\/\/doi.org\/10.1016\/j.annonc.2020.11.005","journal-title":"Ann Oncol"},{"key":"11387_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/WOX.0b013e3182093e19","volume":"4","author":"GW Canonica","year":"2011","unstructured":"Canonica GW, Blaiss M (2011) Antihistaminic, anti-inflammatory, and antiallergic properties of the nonsedating second-generation antihistamine desloratadine: a review of the evidence. World Allergy Organ J 4:47\u201353. https:\/\/doi.org\/10.1097\/WOX.0b013e3182093e19","journal-title":"World Allergy Organ J"},{"key":"11387_CR21","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1159\/000082325","volume":"135","author":"RL Wu","year":"2004","unstructured":"Wu RL, Anthes JC, Kreutner W, Harris AG, West RE Jr. (2004) Desloratadine inhibits constitutive and histamine-stimulated nuclear factor-kappaB activity consistent with inverse agonism at the histamine H1 receptor. Int Arch Allergy Immunol 135:313\u2013318. https:\/\/doi.org\/10.1159\/000082325","journal-title":"Int Arch Allergy Immunol"},{"key":"11387_CR22","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/j.1365-2222.2004.02026.x","volume":"34","author":"DK Agrawal","year":"2004","unstructured":"Agrawal DK (2004) Anti-inflammatory properties of desloratadine. Clin Exp Allergy 34:1342\u20131348. https:\/\/doi.org\/10.1111\/j.1365-2222.2004.02026.x","journal-title":"Clin Exp Allergy"},{"key":"11387_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1067\/mjd.2003.143","volume":"48","author":"E Monroe","year":"2003","unstructured":"Monroe E, Finn A, Patel P, Guerrero R, Ratner P, Bernstein D et al (2003) Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 48:535\u2013541. https:\/\/doi.org\/10.1067\/mjd.2003.143","journal-title":"J Am Acad Dermatol"},{"key":"11387_CR24","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.2165\/00003495-200363190-00010","volume":"63","author":"D Murdoch","year":"2003","unstructured":"Murdoch D, Goa KL, Keam SJ (2003) Desloratadine: an update of its efficacy in the management of allergic disorders. Drugs 63:2051\u20132077. https:\/\/doi.org\/10.2165\/00003495-200363190-00010","journal-title":"Drugs"},{"key":"11387_CR25","doi-asserted-by":"publisher","first-page":"14083","DOI":"10.1038\/s41598-024-64553-z","volume":"14","author":"Y Saito","year":"2024","unstructured":"Saito Y, Takekuma Y, Takahashi M, Oshino T, Sugawara M (2024) Evaluation of the impact of systemic dexamethasone dosage on docetaxel-induced hand-foot syndrome in patients with breast cancer. Sci Rep 14:14083. https:\/\/doi.org\/10.1038\/s41598-024-64553-z","journal-title":"Sci Rep"},{"key":"11387_CR26","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","volume":"71","author":"KK Miller","year":"2014","unstructured":"Miller KK, Gorcey L, McLellan BN (2014) Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol 71:787\u2013794. https:\/\/doi.org\/10.1016\/j.jaad.2014.03.019","journal-title":"J Am Acad Dermatol"},{"key":"11387_CR27","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1097\/01.cad.0000131685.06390.b7","volume":"15","author":"A Ardavanis","year":"2004","unstructured":"Ardavanis A, Tryfonopoulos D, Yiotis I, Gerasimidis G, Baziotis N, Rigatos G (2004) Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs 15:581\u2013585. https:\/\/doi.org\/10.1097\/01.cad.0000131685.06390.b7","journal-title":"Anticancer Drugs"},{"key":"11387_CR28","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000324454","volume":"156","author":"E Syrigou","year":"2011","unstructured":"Syrigou E, Dannos I, Kotteas E, Makrilia N, Tourkantonis I, Dilana K et al (2011) Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 156:320\u2013324. https:\/\/doi.org\/10.1159\/000324454","journal-title":"Int Arch Allergy Immunol"},{"key":"11387_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s10549-014-3190-5","volume":"148","author":"J Mortimer","year":"2014","unstructured":"Mortimer J, Jung J, Yuan Y, Kruper L, Stewart D, Chung S et al (2014) Skin\/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Res Treat 148:563\u2013570. https:\/\/doi.org\/10.1007\/s10549-014-3190-5","journal-title":"Breast Cancer Res Treat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11387-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-11387-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T18:03:09Z","timestamp":1792432989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-11387-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["11387"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-11387-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"19 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board of the Yodogawa Christian Hospital Group with an opt-out option available and was conducted in accordance with the tenets of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest related to this work.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1121"}}